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COGAN'S syndrome is characterized by ocular inflam-
mation. most commonly interstitial keratitis. vestib-
uloauditory symptoms. and (in about 50% of cases) sys-
temic vasculitis. A recent review! cites the evidence for an 
autoimmune pathogenesis of this rare disease. This in-
cludes the presence of lymphocytes in ocular and vestib-
uloauditory tissue.2 and the detection of serum antibodies 
against antigens present in the cornea and inner ear. l 
Successful treatment can be achieved with corti coste-
roids,4 while other immunosuppressive agents. including 
cyclophosphamide and cyclosporine (CyA),s have proved 
useful in severe cases. FK 506 is a powerful new immu-
nosuppressive agent which shares many of the properties 
of Cy A. 0 including a very similar inhibitory effect on CD4'" 
T-Iymphocyte activation and proliferation. In clinical tri-
als. it has proved highly effective in the prevention7 and 
reversals of organ allograft rejection, with a reduced inci-
dence of rejection and fewer side effects compared with 
CyA. FK S06 also shows considerable promise for the 
treatment of certain autoimmune diseases.9-11 including 
disorders unresponsive to high-dose steroids. We report 
here on the successful use of FK 506 in the treatment of a 
patient with Cogan's syndrome. 
A 48-year-old Caucasian woman presented to the Ocular 
Immunology service at the Eye and Ear Institute with a 
9-year history of ocular inflammation. She also had a 
20-year history of hearing loss. She had lost all vision in 
the left eye from intractable glaucoma. which was second-
ary to uncontrolled uveitis and scleritis. 
At the time of presentation. she had active, diffuse 
anterior scleritis. anterior uveitis. and interstitial keratitis 
of the right eye and mild arthralgias of the knees. She was 
on low-dose oral steroids (0.25 mgikg per day). Fluores-
cence Treponima antibody absorption test. rheumatoid 
factor. antinuclear antibodies. and Lyme titer were nega-
tive; and the complete blood count was normal. Audio-
gram was consistent with severe. bilateral sensorineural 
hearing loss. 
She was diagnosed as having Cogan's syndrome and her 
oral steroids were increased to I mg/kg per day. Cardiol-
ogy assessment revealed aortic insufficiency. She became 
dependent on prednisone to.S mg/kg per day) to control her 
ocular inflammation. As the steroid side effects accumu-
lated. she entered our prospective. clinical trial comparing 
the efficacy and safety of oral FK 506 (0.15 mg/kg b.i.d.) 
with conventional immunosuppressive drugs for the treat-
ment of ocular autoimmune disease. She was randomized 
to FK 506. Early during treatment. she experienced a 
pruritic papular rash on her chest. Her ocular inflammation 
began to improve in 3 weeks and was mostly resolved in 3 
months. Over a 100month period. oral steroids were ta-
pered and discontinued. She has had no progression of her 
hearing loss or recurrent arthralgias and has been free of 
ocular inflammation for 6 months. Only minimal systemic 
side effects of FK 506 (> 10 mg BID) have been observed. 
Specifically, there was a transient rise in creatinine to 158 
mmoVL compared with a pretreatment level of 79 mmoVL. 
Renal function responded to a decrease in FK 506 dose; 
her current creatinine level is 106 mmoVL. No change in 
blood pressure. hepatic function. electrolytes. amylase. or 
blood glucose was observed. 
This case report demonstrates the powerful immunosup-
pressive activity and safety of FK 506. It suggests that FK 
506 may prove valuable in the management of this and 
other ocular inflammatory disorders. as well as showing 
promise for the treatment of other autoimmune diseases. 
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